Literature DB >> 15714486

Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.

H Karray1, W Ayadi, L Fki, A Hammami, J Daoud, M M Drira, M Frikha, R Jlidi, J M Middeldorp.   

Abstract

Nasopharyngeal carcinoma (NPC) in Tunisia is characterized by its bimodal age distribution involving juvenile patients of 10-24 years and adult patients of 40-60 years. Three serological techniques were compared for primary diagnosis (N = 117) and post-treatment monitoring (N = 21) of NPC patients separated in two age groups. Immunofluorescence assay (IFA) was used as the "gold standard" for detection of IgG and IgA antibodies reactive with Epstein-Barr virus (EBV) early (EA) and viral capsid (VCA) antigens. Results were compared with ELISA measuring IgG and IgA antibody reactivity to defined EBNA1, EA, and VCA antigens. Immunoblot was used to reveal the molecular diversity underlying the anti-EBV IgG and IgA antibody responses. The results indicate that young NPC patients have significantly more restricted anti-EBV IgG and IgA antibody responses with aberrant IgG VCA/EA levels in 78% compared to 91.7% in elder patients. IgA VCA/EA was detected in 50% of young patients versus 89.4% for the elder group (P < 0.001). Immunoblot revealed a reduced overall diversity of EBV antigen recognition for both IgG and IgA in young patients. A good concordance was observed between ELISA and IFA for primary NPC diagnosis with 81-91% overall agreement. Even better agreement (95-100%) was found for antibody changes during follow-up monitoring, showing declining reactivity in patients in remission and increasing reactivity in patients with persistent disease or relapse. ELISA for IgA anti-VCA-p18 and immunoblot proved most sensitive for predicting tumor relapse. VCA-p18 IgA ELISA seems suitable for routine diagnosis and early detection of NPC complication. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15714486     DOI: 10.1002/jmv.20310

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.

Authors:  Nehla Mokni Baizig; Patrice Morand; Jean Marie Seigneurin; Hamouda Boussen; Asma Fourati; Said Gritli; Zeineb Oueslati; Slim Touati; Amor Gamoudi; Mansour Ben Abdallah; Michèle El May; Ahmed El May
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-30       Impact factor: 2.503

Review 2.  Update in pediatric nasopharyngeal undifferentiated carcinoma.

Authors:  Line Claude; Emmanuel Jouglar; Loig Duverge; Daniel Orbach
Journal:  Br J Radiol       Date:  2019-07-31       Impact factor: 3.039

3.  Tumor microenvironment contributes to Epstein-Barr virus anti-nuclear antigen-1 antibody production in nasopharyngeal carcinoma.

Authors:  Ping Ai; Zhiping Li; Yong Jiang; Changping Song; Lin Zhang; Huaizhong Hu; Tao Wang
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

4.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

5.  Over-expression of miR-10b in NPC patients: correlation with LMP1 and Twist1.

Authors:  Nesrine Allaya; Abdelmajid Khabir; Tahia Sallemi-Boudawara; Noura Sellami; Jamel Daoud; Abdelmonem Ghorbel; Mounir Frikha; Ali Gargouri; Raja Mokdad-Gargouri; Wajdi Ayadi
Journal:  Tumour Biol       Date:  2015-01-20

6.  CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression.

Authors:  Hend Braham; Mounir Trimeche; Sonia Ziadi; Sarra Mestiri; Moncef Mokni; Khaled Amara; Mohamed Hachana; Badreddine Sriha; Sadok Korbi
Journal:  Virchows Arch       Date:  2006-05-04       Impact factor: 4.064

7.  Nasopharyngeal cancer-derived microRNA-21 promotes immune suppressive B cells.

Authors:  Bei-Ping Miao; Rui-Shi Zhang; Meng Li; Yun-Ting Fu; Miao Zhao; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

8.  Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.

Authors:  Dewi K Paramita; Jajah Fachiroh; Sofia M Haryana; Jaap M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

9.  Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.

Authors:  J Fachiroh; P R Prasetyanti; D K Paramita; A T Prasetyawati; D W Anggrahini; S M Haryana; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

10.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Authors:  Ai-Di Gu; Li-Xia Lu; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Wei-Hua Jia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.